1. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. (3rd October 2017) Authors: Handelsman, Yehuda; Lauring, Brett; Gantz, Ira; Iredale, Carol; O'Neill, Edward A.; Wei, Ziwen; Suryawanshi, Shailaja; Kaufman, Keith D.; Engel, Samuel S.; Lai, Eseng Journal: Current medical research and opinion Issue: Volume 33:Number 10(2017) Page Start: 1861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Issue 3 (2nd October 2017) Authors: Rosenstock, Julio; Frias, Juan; Páll, Dénes; Charbonnel, Bernard; Pascu, Raluca; Saur, Didier; Darekar, Amanda; Huyck, Susan; Shi, Harry; Lauring, Brett; Terra, Steven G. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 3(2018) Page Start: 520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study. Issue 3 (23rd October 2017) Authors: Dagogo‐Jack, Samuel; Liu, Jie; Eldor, Roy; Amorin, Guillermo; Johnson, Jeremy; Hille, Darcy; Liao, Yuqin; Huyck, Susan; Golm, Gregory; Terra, Steven G.; Mancuso, James P.; Engel, Samuel S.; Lauring, Brett Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 3(2018) Page Start: 530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Issue 5 (25th January 2018) Authors: Pratley, Richard E.; Eldor, Roy; Raji, Annaswamy; Golm, Gregory; Huyck, Susan B.; Qiu, Yanping; Sunga, Sheila; Johnson, Jeremy; Terra, Steven G.; Mancuso, James P.; Engel, Samuel S.; Lauring, Brett Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 5(2018) Page Start: 1111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. (6th June 2014) Authors: Lauring, Brett; Li, Xiujiang (Susie); Liu, Yang; Corr, Christy; Lazarus, Nicole; Cote, Josee; Larson, Patrick; Levonas, Amy O. Johnson; Lasseter, Kenneth C.; Preston, Richard A.; Smith, William B.; Lai, Eseng; Wagner, John A. Journal: Journal of clinical pharmacology Issue: Volume 54:Number 11(2014:Nov.) Page Start: 1247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial. Issue 4 (14th February 2019) Authors: Gallo, Silvina; Charbonnel, Bernard; Goldman, Allison; Shi, Harry; Huyck, Susan; Darekar, Amanda; Lauring, Brett; Terra, Steven G. Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 4(2019) Page Start: 1027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Issue 6 (23rd February 2018) Authors: Aronson, Ronnie; Frias, Juan; Goldman, Allison; Darekar, Amanda; Lauring, Brett; Terra, Steven G. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 6(2018) Page Start: 1453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Issue 5 (22nd February 2017) Authors: Terra, Steven G.; Focht, Kristen; Davies, Melanie; Frias, Juan; Derosa, Giuseppe; Darekar, Amanda; Golm, Gregory; Johnson, Jeremy; Saur, Didier; Lauring, Brett; Dagogo‐Jack, Sam Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 5(2017) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. (3rd August 2019) Authors: Hollander, Priscilla; Hill, Julie; Johnson, Jeremy; Wei Jiang, Zhi; Golm, Gregory; Huyck, Susan; Terra, Steven G.; Mancuso, James P.; Engel, Samuel S.; Lauring, Brett; Liu, Jie Journal: Current medical research and opinion Issue: Volume 35:Number 8(2019) Page Start: 1335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Issue 6 (5th April 2019) Authors: Ji, Linong; Liu, Yanmei; Miao, Heng; Xie, Yongli; Yang, Ming; Wang, Wei; Mu, Yuting; Yan, Ping; Pan, Sharon; Lauring, Brett; Liu, Shu; Huyck, Susan; Qiu, Yanping; Terra, Steven G. Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 6(2019) Page Start: 1474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗